title: Is statin use really associated with efficacy of rituximab?
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Asai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Terui
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ennishi
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D015986:Confounding Factors, Epidemiologic; D004336:Drug Antagonism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D012107:Research Design; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069283:Rituximab